ArticleMaedica2023
Current Knowledge of Heart Failure with Preserved Ejection Fraction.
Article in Maedica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) is the most common type of heart failure (HF) - predominantly in the elderly population - and the most difficult to treat. The diagnosis is based, apart from clinical data, on data provided by imaging and biochemical evaluation: left ventricular (LV) diastolic dysfunction, EF ≥50% and increase of natriuretic peptide (NP). Several phenotypes of HFpEF have been identified based on etiological and pathophysiological data. Defining the phenotypes has allowed a wider knowledge of specific pathogenic mechanisms and conducting therapeutic studies with pharmacological and non-pharmacological agents . but with uncertain results. The diagnosis is based, apart from clinical data, on data provided by imaging and biochemical evaluation: left ventricular (LV) diastolic dysfunction, EF ≥50% and increase of natriuretic peptide (NP). Several phenotypes of HFpEF have been identified based on etiological and pathophysiological data. Defining the phenotypes has allowed a wider knowledge of specific pathogenic mechanisms and conducting therapeutic studies with pharmacological and non-pharmacological agents . but with uncertain results.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.